SLC5A2 and type 2 diabetes mellitus: Fortunately, new medications used in the treatment of type II diabetes, such as glucagon-like peptide 1 (GLP-1) analogs, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, and the long-known metformin, are much less likely to induce hypoglycemia, since they do not unconditionally stimulate insulin secretion [147].